Tandem Diabetes Care Inc (FRA:TD5A)
€ 46.5 -0.61 (-1.29%) Market Cap: 3.09 Bil Enterprise Value: 3.10 Bil PE Ratio: 0 PB Ratio: 13.74 GF Score: 77/100

Tandem Diabetes Care Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 17, 2021 / 06:30PM GMT
Release Date Price: €72.73 (+0.03%)
Steven Michael Lichtman
Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst

Hi, everyone. This is Steve Lichtman, medical devices analyst at Oppenheimer. Welcome to the 31st Annual Oppenheimer Healthcare Conference. Very happy to have with us up next Tandem Diabetes Care. With us today is John Sheridan, President and CEO; and Leigh Vosseller, Executive Vice President and Chief Financial Officer. We will have a few slides up here upfront, and then we'll go into Q&A. If you do have a question, please key them in, and I'll get them right over to John and Leigh.

With that, I'm going to turn the podium over to John.

John F. Sheridan
Tandem Diabetes Care, Inc. - President, CEO & Director

Thanks, Steve. It's great to see you. And good morning, everybody. I'll just start off by saying that 2020 was a remarkable year for Tandem. We nearly eclipsed $500 million in sales. We launched Control-IQ, which is clearly the most advanced commercially available automated insulin delivery system. We have over 200,000 people using Tandem's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot